| | Webinar: Removing Antibody Drug Discovery's DNA Bottleneck Tuesday, September 14 | 2pm ET / 11am PT GPCRs have proven to be one of the most challenging targets for antibody drug development. In this webinar, we describe the use of next-generation DNA synthesis tools to overcome the DNA bottleneck in antibody-based GPCR drug discovery. Learn More. |
Despite mixed phase 3 showing, Apellis hopes to push eye disorder drug past FDA's finish line Orchard picks an apple from Novartis' field with new chief technical officer Louisiana revokes licenses from 7 nursing homes after Ida evacuation failures cost lives Biogen CEO blames Aduhelm’s rocky launch on 'too much confusion, misinformation and controversy' Cardiff reveals early data on challenger to Amgen's KRAS crown Acorda slashes jobs again as generics hamper sales of MS drug Sanford Health receives $350M for virtual care center to support rural health COVID-19 tracker: Moderna's combo shot could hit clinic within a year; AZ criticizes booster rollout Pediatric teletherapy provider DotCom Therapy raises $13M backed by LRVHealth, OSF Ventures AstraZeneca's COVID-19 shot joins the list of vaccines flagged for rare Guillain-Barre syndrome Centessa eyes registration in hemophilia as SerpinPC shows reduction of bleeding in phase 2 study HHS aims to use value-based care payment models to lower drug prices Featured Story | By Noah Higgins-Dunn Apellis Pharmaceuticals’ pegcetacoplan posted mixed results in two late-stage trials studying the C3 inhibitor in patients living with geographic atrophy (GA). Despite the mixed showing, CEO Cedric Francois thinks the med's performance was strong enough to warrant an FDA nod. read more |
| |
|---|
|
Top Stories By Kyle LaHucik Gene therapy biotech Orchard Therapeutics has picked a shiny apple from Novartis, bringing Nicoletta Loggia, Ph.D. on as chief technical officer after a 17-year career at the Swiss pharma. Loggia previously served as global head of cell and gene therapies for Novartis—a high profile part of the pharma's business that in recent years has launched Zolgensma. read more By Dave Muoio All seven nursing homes evacuated hundreds of residents to a single overcrowded facility, where surveyors observed unacceptable care and faced threats from ownership, according to the state health department. read more By Eric Sagonowsky Before Biogen scored an FDA approval for Alzheimer's drug aducanumab, the company probably hoped its launch would go much smoother than the last three months have been. It turns out Biogen's CEO Michel Vounatsos is willing to say so publicly. read more By Annalee Armstrong Amgen has already won the KRAS race by getting Lumakras across the finish line, but Cardiff Oncology has just rolled out some early data for a follow-on candidate showing partial responses and extended survival without disease progression compared to standard of care. read more By Kyle LaHucik Acorda Therapeutics is restructuring yet again as sales for its multiple sclerosis and Parkinson's drugs continue to fall below expectations. The pharma is cutting 15% of its workforce after already reducing headcount by 16% in January. read more By Anastassia Gliadkovskaya The virtual care center will serve patients in Sanford Health’s network, and will also be the home base of several innovation, education and research initiatives aimed at advancing digital healthcare. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner Moderna expects to begin clinical testing of a combination flu/COVID-19 booster shot in 6 to 12 months. AstraZeneca CEO Pascal Soriot said rollouts of COVID-19 boosters are premature. Australia prime minister Scott Morrison is feeling more heat over the country's slow vaccine rollout. Plus more headlines. read more By Emmy Lucas DotCom Therapy secured $13 million in its series A financing to grow and scale its pediatric teletherapy platform. read more By Kevin Dunleavy The EMA has warned of a possible link between the AstraZeneca COVID-19 vaccine and the rare nerve disorder Guillain-Barre syndrome. The Johnson & Johnson COVID shot, as well as some non-COVID vaccines, also have been linked to the condition. read more By Kyle LaHucik Centessa Pharmaceuticals' hemophilia drug reduced bleeding rates and spontaneous joint bleeds in a midstage study, setting the biotech up to move the candidate closer to regulatory submission. read more By Robert King HHS wants value-based care payment models to help lower drug prices and is considering new models that tie reimbursement to patient outcomes and incentivize generic and biosimilar use. read more | 